Certain batches of NovoPen Echo insulin cartridge holders are being recalled by the manufacturer because they may crack or break if exposed to certain chemicals, such as cleaning agents, the FDA ... The FDA also announced on May 19 that it approved the
Canagliflozin (Invokana, Invokamet) increases patients' risk of leg and foot amputations, according to new data from two clinical trials, the FDA recently announced. ... Canagliflozin (Invokana, Invokamet) increases the risk of leg and foot amputations
The first FDA-approved continuous glucose monitoring system with a fully implantable glucose sensor has been cleared for use in adults with diabetes, the agency announced on June 21.
The FDA has approved the first treatment for severe hypoglycemia that can be administered without an injection, the agency announced on July 24.
Patients should not use unapproved or unauthorized devices for diabetes management, either alone or with authorized devices, the FDA recently warned. ... In one report, a patient used an unauthorized device that received the electronic signal from an
The clinical study did not meet its original end point, but the FDA concluded that the benefits outweighed risks of the device, according to a press release. ... Other adverse events included pain, heartburn, problems swallowing, belching, mild nausea,
The FDA has approved an oral formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, to help improve blood glucose control in adults with type 2 diabetes. ... The FDA recently approved semaglutide (Rybelsus) oral tablets, the
An ongoing clinical trial found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with canagliflozin (Invokana, Invokamet), according to an FDA safety alert.
Empagliflozin (Jardiance) is approved for a new indication—to reduce the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease, the FDA announced on Dec. ... The most common side effects are urinary tract infections and
Insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg 70/30) were approved by the FDA on Sept. ... Both drugs are contraindicated for patients with diabetic ketoacidosis, according to an FDA.